FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Sinclair Michael 2. Issuer Name and Ticker or Trading Symbol OPIANT PHARMACEUTICALS, INC. [ OPNT ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O OPIANT PHARMACEUTICALS, INC., 233 WILSHIRE BLVD, SUITE 280
3. Date of Earliest Transaction (MM/DD/YYYY)
8/23/2021
(Street)
SANTA MONICA, CA 90401
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.001 per share  8/23/2021    M    65124  A $5  209194  D   
Common Stock, par value $0.001 per share  8/23/2021    S    65124  D $16.50 (1) 144070  D   
Common Stock, par value $0.001 per share  8/24/2021    M    34607  A $5  178677  D   
Common Stock, par value $0.001 per share  8/24/2021    S    34607  D $15.71 (2) 144070  D   
Common Stock, par value $0.001 per share  8/25/2021    M    50269  A $5  194339  D   
Common Stock, par value $0.001 per share  8/25/2021    S    50269  D $14.69 (3) 144070  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options  $5.0  8/23/2021    M        65124   6/15/2014 (4) 6/14/2024  Common Stock, par value $0.001 per share  65124.0  $0  84876  D   
Options  $5.0  8/24/2021    M        34607   6/15/2014 (4) 6/14/2024  Common Stock, par value $0.001 per share  34607.0  $0  50269  D   
Options  $5.0  8/25/2021    M        50269   6/15/2014 (4) 6/14/2024  Common Stock, par value $0.001 per share  50269.0  $0  0  D   

Explanation of Responses:
(1)  This transaction was executed in multiple trades at prices ranging from $16.00 to $17.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(2)  This transaction was executed in multiple trades at prices ranging from $15.50 to $16.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(3)  This transaction was executed in multiple trades at prices ranging from $13.80 to $15.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(4)  These options became exercisable on December 15, 2014 when Opiant Pharmaceuticals entered into a distribution, licensing, royalty, partnership, collaboration, or other significant transaction with respect to the opioid overdose reversal treatment with Adapt Pharma Operations Limited.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Sinclair Michael
C/O OPIANT PHARMACEUTICALS, INC.
233 WILSHIRE BLVD, SUITE 280
SANTA MONICA, CA 90401
X X


Signatures
/s/ Michael Sinclair 8/25/2021
**Signature of Reporting Person Date
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Opiant Pharmaceuticals Charts.
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Opiant Pharmaceuticals Charts.